SFM
OVID icon

Sphera Funds Management’s Ovid Therapeutics OVID Stock Holding History

Sphera Funds Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.64M Sell
1,353,000
-269,828
-17% -$696K 0.47% 73
2026
Q1 		$3.6M Buy
+1,622,828
New +$2.9M 0.57% 61
2018
Q1 		– Sell
-180,674
Closed -$1.78M – 131
2017
Q4 		$1.78M Sell
180,674
-125,000
-41% -$1.15M 0.21% 99
2017
Q3 		$2.62M Hold
305,674
– – 0.37% 72
2017
Q2 		$3.04M Buy
+305,674
New +$3.99M 0.52% 60

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Sphera Funds Management's OVID Position: Q2 2026 in Review

Sphera Funds Management reduced its Ovid Therapeutics (OVID) stake by 17% in Q2 2026, selling an estimated $696K and leaving 1,353,000 shares worth $3.64M. The position accounts for 0.47% of the portfolio, ranked #73.

Sphera Funds Management first reported a position in OVID in Q2 2017 and has held it in 5 quarters since. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Sphera Funds Management held 1,353,000 shares of Ovid Therapeutics worth $3.64M as of Q2 2026.
  • Sphera Funds Management sold 269,828 Ovid Therapeutics shares in Q2 2026, an estimated $696K.
  • Ovid Therapeutics made up 0.47% of Sphera Funds Management's portfolio in Q2 2026, its #73 holding.
  • Sphera Funds Management first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 5 quarters since.
  • 131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.